Mauro Mansutti - Concepedia

Author

Mauro Mansutti

Ospedale Santa Maria della Misericordia di Udine ORCID

Also Known As

M Mansutti, M. Mansutti, Mauro Mansutti

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Ospedale Santa Maria della Misericordia di Udine Ospedale Policlinico San Martino Istituti di Ricovero e Cura a Carattere Scientifico Fondazione Michelangelo Ospedale Sacro Cuore Don Calabria

About

Mauro Mansutti is an author at Ospedale Santa Maria della Misericordia di Udine specializing in breast cancer, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.9K
2	Health Sciences	3	3	1.5K
3	Endocrinology	2	2	36
4	Public Health	1	1	14
5	Epidemiology	1	1	14

Mauro Mansutti

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Luca Gianni, W. Eiermann, Alexey Manikhas, The Lancet Noah TrialBreast OncologyOncologyClinical TrialsBreast Cancer	2010	1.2K
AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer Luca Gianni, Gilles Romieu, Sérgio Serrano, Journal of Clinical Oncology First-line TherapyBreast OncologyMedicineImmunologyClinical Trials	2013	255
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study Luca Gianni, Giancarlo Bisagni, Marco Colleoni, The Lancet Oncology Breast OncologyMedicinePharmacologyNeoadjuvant TreatmentBreast Cancer	2018	167
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial Luca Gianni, Mauro Mansutti, Antonio Antón, JAMA Oncology	2018	153
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial Lucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, The Lancet Oncology Breast OncologyOncologyPostmenopausal PatientsGynecologyAdjuvant Treatment	2021	82
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer Federico Cappuzzo, Francesca Mazzoni, Alessandra Gennari, British Journal of Cancer	2004	49
S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC) Luca Gianni, Gilles Romieu, M. Lichinitser, Cancer Research First-line TherapyBreast OncologyCancer ManagementPathologyPharmacotherapy	2011	38
A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer Sara Cresta, Giacomo Grasselli, Mauro Mansutti, Annals of Oncology	2004	38
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer M. Venturini, Claudia Bighin, Fabio Puglisi, The Breast	2010	32
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer Luca Gianni, Marco Colleoni, Giancarlo Bisagni, npj Breast Cancer	2022	27

Page 1